MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?Zacks Investment Research • 11/05/26
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial24/7 Wall Street • 11/03/26
Merck's Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.24/7 Wall Street • 11/03/26
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of ExacerbationsBusiness Wire • 11/03/26
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026Business Wire • 11/02/26
$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends24/7 Wall Street • 10/30/26
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up24/7 Wall Street • 10/30/26
Merck Q3 Earnings Call Highlights Pipeline Progress and Raised OutlookZacks Investment Research • 10/30/26
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price DropBusiness Wire • 10/30/26
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?Zacks Investment Research • 10/29/26
MRK Q3 Earnings & Sales Beat Estimates, '26 EPS View Raised, Stock UpZacks Investment Research • 10/29/26
Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher24/7 Wall Street • 10/29/26